Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two women in the lab with equipment

The MDC works in partnership with many academic and biotech industries to supply patented technologies to Oxford researchers. These new technologies are clinically accredited diagnostics, and are a result of partnerships with:

  • Base Genomics – Supplying patented TAPS methylation assays
  • Illumina – Supplying next generation sequencing platform support
  • Oxford Nanopore – Supplying hand-held diagnostic whole genome sequencing technology for applications in Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic Leukaemia and haemoglobinopathies
  • Adaptive Biotech – Only UK site, based within the OMDC in Oxford, licensed to supply of measurable residual disease, T-Cell Receptor and B-Cell Receptor clonality assays
  • Genomics England – Supplying whole genome sequencing technology
  • Oxford Genomics Centre – supplying high-throughput, whole genome & next generation sequencing
  • Mologic – supplying COVID-19 antibody testing technology

We also have access to patented technology, developed in part by the OMDC, which include:

  • Non-invasive Prenatal Testing ® – foetal DNA analysis
  • AlexaPath – imaging of tumour samples in Africa